Incretin-based therapies — GLP-1 receptor agonists like semaglutide and tirzepatide, along with emerging multi-agonists — produce weight loss comparable to bariatric surgery, but raise a clinically important question: how much of that lost weight is contractile muscle versus fat? Korean endocrinologists at Samsung Medical Center synthesize available evidence showing these drugs preferentially reduce fat mass, relatively preserve lean mass, and may improve muscle quality by reducing myosteatosis (intramuscular fat infiltration) — a distinction that raw lean-mass numbers on DEXA scans often obscure.
The broader significance lies in timing. GLP-1 prescriptions are now at population scale, yet long-term functional muscle data — grip strength trajectories, gait speed, fall incidence — remain sparse, particularly in older adults and those with already-reduced muscle reserve, precisely the populations most vulnerable to sarcopenia's consequences. The medical literature has long established that rapid weight loss without resistance training accelerates muscle loss regardless of mechanism; incretin drugs are no exception to this physiology. What remains genuinely uncertain is whether their insulin-sensitizing, anti-inflammatory, and anti-myosteatotic properties partially counteract this universal weight-loss liability.
This analysis is confirmatory-with-nuance rather than paradigm-shifting — it reframes lean-mass loss as not automatically equivalent to functional muscle loss, a methodologically important distinction. For adults over 50 using these medications, the practical implication is clear: resistance training and adequate protein intake aren't optional adjuncts; they're mechanistically necessary co-interventions.
